459 related articles for article (PubMed ID: 23379292)
1. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
Hanke CW; Narins RS; Brandt F; Cohen JL; Donofrio LM; Downie J; Heinz M; Harrington L; McDaniel DH; Nestor M; Schlessinger J; Schlöbe A; Taub A; Weiss RA
Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of incobotulinumtoxinA for treatment of glabellar frown lines: a post hoc pooled analysis of 2 randomized, placebo-controlled, phase 3 trials.
Jones D; Carruthers J; Narins RS; Coleman WP; Harrington L; Brandt FS; Cohen JL
Dermatol Surg; 2014 Jul; 40(7):776-85. PubMed ID: 25111351
[TBL] [Abstract][Full Text] [Related]
4. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
Prager W; Rappl T
J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
[TBL] [Abstract][Full Text] [Related]
5. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study.
Prager W; Bee EK; Havermann I; Zschocke I
Clin Interv Aging; 2013; 8():449-56. PubMed ID: 23650444
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a Randomized, Double-Blind, Placebo-Controlled, Phase III Study.
Kerscher M; Rzany B; Prager W; Turnbull C; Trevidic P; Inglefield C
Dermatol Surg; 2015 Oct; 41(10):1149-57. PubMed ID: 26359996
[TBL] [Abstract][Full Text] [Related]
7. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines.
Sattler G; Callander MJ; Grablowitz D; Walker T; Bee EK; Rzany B; Flynn TC; Carruthers A
Dermatol Surg; 2010 Dec; 36 Suppl 4():2146-54. PubMed ID: 21134045
[TBL] [Abstract][Full Text] [Related]
8. IncobotulinumtoxinA in esthetics.
Kerscher M; Yutskovskaya Y; Flynn TC
J Drugs Dermatol; 2013 Jun; 12(6):e111-20. PubMed ID: 23839200
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of IncobotulinumtoxinA for the treatment of platysmal bands of the aging neck: an open-label, prospective pilot study.
Gubanova EI; Panova OS; Sanchez EA; Rodina MY; Starovatova PA
J Drugs Dermatol; 2013 Dec; 12(12):1461-6. PubMed ID: 24301249
[TBL] [Abstract][Full Text] [Related]
10. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.
Rzany B; Flynn TC; Schlöbe A; Heinz M; Harrington L
Dermatol Surg; 2013 Jan; 39(1 Pt 1):95-103. PubMed ID: 23190342
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study.
Won CH; Lee HM; Lee WS; Kang H; Kim BJ; Kim WS; Lee JH; Lee DH; Huh CH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):171-8. PubMed ID: 23301821
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
[TBL] [Abstract][Full Text] [Related]
13. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines.
Kerscher M; Fabi S; Fischer T; Gold M; Joseph J; Prager W; Rzany B; Yoelin S; Roll S; Klein G; Maas C
J Drugs Dermatol; 2020 Oct; 19(10):985-991. PubMed ID: 33026771
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.
Kane MA; Gold MH; Coleman WP; Jones DH; Tanghetti EA; Alster TS; Rohrer TE; Burgess CM; Shamban AT; Finn E
Dermatol Surg; 2015 Nov; 41(11):1310-9. PubMed ID: 26509943
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
[TBL] [Abstract][Full Text] [Related]
16. Multicentre, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
Fulford-Smith A; Gallagher CJ; Brin MF
Dermatol Surg; 2013 Jul; 39(7):1118-9. PubMed ID: 23725480
[No Abstract] [Full Text] [Related]
17. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
[TBL] [Abstract][Full Text] [Related]
18. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
Rzany BJ; Ascher B; Avelar RL; Bergdahl J; Bertucci V; Bodokh I; Carruthers JA; Cartier H; Delmar H; Denfeld R; Gross JE; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Sattler G; Sebastian M; Solish N; Swift A; Trévidic P
Aesthet Surg J; 2020 Mar; 40(4):413-429. PubMed ID: 30951166
[TBL] [Abstract][Full Text] [Related]
19. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety.
Brandt F; Swanson N; Baumann L; Huber B
Dermatol Surg; 2009 Dec; 35(12):1893-901. PubMed ID: 19549186
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
Dessy LA; Fallico N; Mazzocchi M; Scuderi N
Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
